PTC Therapeutics Guides $700–$800M 2026 Revenue, Seeks FDA Study for Vitiquinone
PTC Therapeutics forecasts 2026 product revenue of $700–$800 million, driven primarily by Safiance, reflecting 19–36% growth and a global rollout in 20–30 countries by year-end. The FDA has requested an open-label study for Vitiquinone and the company faces regulatory alignment on study endpoints for pipeline programs like Vodalam.
1. 2026 Revenue Guidance
PTC Therapeutics projects product revenue of $700–$800 million for 2026, representing 19–36% growth over 2025. Safiance is expected to drive the majority of U.S. revenue, with guidance deemed conservative pending further visibility into the DMD franchise.
2. Safiance Global Launch Progress
The company plans commercial patient launches in 20–30 countries by year-end, with specialty centers reporting strong responses in severe patients. International contributions are anticipated in the latter half of 2026 as pricing and reimbursement negotiations conclude.
3. FDA Study Requirement for Vitiquinone
The FDA has suggested an open-label or single-arm study using a natural history control to provide additional data for Vitiquinone while avoiding placebo in young patients. PTC Therapeutics plans to finalize the study protocol in Q2, including matching criteria with its natural history database.
4. Pipeline Development and Regulatory Alignment
PTC continues to advance its R&D pipeline, including Vodalam for Huntington’s disease and multiple innovative platforms slated for 2026. Aligning with the FDA on study designs and endpoints remains critical to mitigating development timeline risks.